Gujarat Themis Biosyn Limited (NSE:GUJTHEM)

Market Cap	49.58B
Revenue (ttm)	1.48B
Net Income (ttm)	445.97M
Shares Out	n/a
EPS (ttm)	4.10
PE Ratio	111.18
Forward PE	n/a
Dividend	0.67 (0.15%)
Ex-Dividend Date	Sep 4, 2025

Volume	4,608
Average Volume	290,407
Open	450.00
Previous Close	452.30
Day's Range	450.00 - 457.90
52-Week Range	208.00 - 465.00
Beta	-0.37
RSI	68.17
Earnings Date	Nov 14, 2025

About Gujarat Themis Biosyn

Gujarat Themis Biosyn Limited engages in the manufacture of pharmaceuticals and medicinal chemicals in India. The company offers bulk drugs on job work basis in India. Its products include Rifamycin-S, an intermediate for the treatment of tuberculosis, Mycobacterium avium complex, leprosy, and Legionnaires' disease; Rifamycin-O for the treatment of traveler's diarrhea, irritable bowel syndrome, and hepatic encephalopathy; and Lovastatin. The company was incorporated in 1981 and is based in Mumbai, India.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1981
• Employees: 221
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: GUJTHEM

Financial Performance

In 2024, Gujarat Themis Biosyn's revenue was 1.51 billion, a decrease of -11.20% compared to the previous year's 1.70 billion. Earnings were 487.72 million, a decrease of -17.56%.